CIPROFLOXACIN EXTENDED RELEASE Drug Patent Profile
✉ Email this page to a colleague
When do Ciprofloxacin Extended Release patents expire, and what generic alternatives are available?
Ciprofloxacin Extended Release is a drug marketed by Ani Pharms, Dr Reddys Labs Ltd, Endo Operations, Fosun Pharma, and Rising. and is included in five NDAs.
The generic ingredient in CIPROFLOXACIN EXTENDED RELEASE is ciprofloxacin; ciprofloxacin hydrochloride. There are thirty-four drug master file entries for this compound. Additional details are available on the ciprofloxacin; ciprofloxacin hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CIPROFLOXACIN EXTENDED RELEASE?
- What are the global sales for CIPROFLOXACIN EXTENDED RELEASE?
- What is Average Wholesale Price for CIPROFLOXACIN EXTENDED RELEASE?
Summary for CIPROFLOXACIN EXTENDED RELEASE
US Patents: | 0 |
Applicants: | 5 |
NDAs: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 123 |
Clinical Trials: | 18 |
DailyMed Link: | CIPROFLOXACIN EXTENDED RELEASE at DailyMed |
Recent Clinical Trials for CIPROFLOXACIN EXTENDED RELEASE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
British University In Egypt | Early Phase 1 |
Future University in Egypt | Phase 1 |
Cairo University | N/A |